Establishment Labs Holdings Inc.

NasdaqCM:ESTA Stock Report

Market Cap: US$2.6b

Establishment Labs Holdings Valuation

Is ESTA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of ESTA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: ESTA ($85.81) is trading above our estimate of future cash flow value ($53)

Significantly Below Future Cash Flow Value: ESTA is trading above our estimate of future cash flow value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ESTA?

Key metric: As ESTA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ESTA. This is calculated by dividing ESTA's market cap by their current revenue.
What is ESTA's PS Ratio?
PS Ratio11x
SalesUS$229.58m
Market CapUS$2.57b

Price to Sales Ratio vs Peers

How does ESTA's PS Ratio compare to its peers?

The above table shows the PS ratio for ESTA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.7x
NEOG Neogen
2.2x-1.30%US$2.0b
HAE Haemonetics
2.6x5.04%US$3.4b
XRAY DENTSPLY SIRONA
0.6x1.18%US$2.2b
MMED MiniMed Group
1.4x8.78%US$4.2b
ESTA Establishment Labs Holdings
11x21.90%US$2.6b

Price-To-Sales vs Peers: ESTA is expensive based on its Price-To-Sales Ratio (11x) compared to the peer average (1.7x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does ESTA's PS Ratio compare vs other companies in the US Medical Equipment Industry?

58 CompaniesPrice / SalesEstimated GrowthMarket Cap
XRAY DENTSPLY SIRONA
0.6x1.18%US$2.17b
ENOV Enovis
0.5x4.59%US$1.27b
QDEL QuidelOrtho
0.4x3.54%US$1.24b
VREX Varex Imaging
0.5x3.37%US$420.62m
ESTA 11.0xIndustry Avg. 2.7xNo. of Companies58PS02.85.68.411.214+
58 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ESTA is expensive based on its Price-To-Sales Ratio (11x) compared to the US Medical Equipment industry average (2.7x).

Price to Sales Ratio vs Fair Ratio

What is ESTA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ESTA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio11x
Fair PS Ratio5.7x

Price-To-Sales vs Fair Ratio: ESTA is expensive based on its Price-To-Sales Ratio (11x) compared to the estimated Fair Price-To-Sales Ratio (5.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ESTA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$85.81
US$91.22
+6.31%
8.64%US$100.00US$76.00n/a9
Jun ’27US$68.08
US$90.11
+32.36%
8.04%US$100.00US$76.00n/a9
May ’27US$70.23
US$88.00
+25.30%
10.62%US$100.00US$65.00n/a9
Apr ’27US$58.70
US$89.00
+51.62%
7.89%US$100.00US$74.00n/a9
Mar ’27US$78.70
US$89.78
+14.08%
6.19%US$100.00US$81.00n/a9
Feb ’27US$68.15
US$83.25
+22.16%
5.78%US$90.00US$75.00n/a8
Jan ’27US$72.88
US$82.00
+12.51%
6.80%US$90.00US$75.00n/a9
Dec ’26US$67.79
US$74.22
+9.49%
8.44%US$85.00US$62.00n/a9
Nov ’26US$47.95
US$55.78
+16.32%
15.72%US$70.00US$43.00n/a9
Oct ’26US$40.82
US$55.44
+35.83%
16.75%US$70.00US$40.00n/a9
Sep ’26US$41.27
US$55.44
+34.35%
16.75%US$70.00US$40.00n/a9
Aug ’26US$41.34
US$56.25
+36.07%
14.60%US$70.00US$45.00n/a8
Jul ’26US$43.40
US$54.50
+25.58%
18.12%US$70.00US$38.00n/a8
Jun ’26US$34.42
US$53.00
+53.98%
15.42%US$62.00US$38.00US$68.088
May ’26US$31.04
US$55.00
+77.19%
14.05%US$62.00US$38.00US$70.237
Apr ’26US$40.11
US$55.57
+38.55%
11.70%US$62.00US$42.00US$58.707
Mar ’26US$42.87
US$57.71
+34.63%
16.33%US$75.00US$42.00US$78.707
Feb ’26US$32.05
US$60.00
+87.21%
15.76%US$75.00US$46.00US$68.157
Jan ’26US$46.07
US$60.29
+30.86%
15.32%US$75.00US$46.00US$72.887
Dec ’25US$45.89
US$60.29
+31.37%
15.32%US$75.00US$46.00US$67.797
Nov ’25US$45.42
US$62.83
+38.34%
15.25%US$75.00US$50.00US$47.956
Oct ’25US$40.56
US$62.33
+53.68%
15.29%US$75.00US$50.00US$40.826
Sep ’25US$45.82
US$60.43
+31.88%
15.99%US$75.00US$45.00US$41.277
Aug ’25US$42.51
US$64.43
+51.56%
11.46%US$75.00US$50.00US$41.347
Jul ’25US$43.34
US$65.14
+50.31%
7.31%US$75.00US$60.00US$43.407
Jun ’25US$52.23
US$63.00
+20.62%
4.49%US$68.00US$60.00US$34.427
US$91.22
Fair Value
5.9% undervalued intrinsic discount
9
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/30 21:57
End of Day Share Price 2026/06/30 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Establishment Labs Holdings Inc. is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Neil ChatterjiB. Riley Securities, Inc.
Sam EiberBTIG
Michael GormanBTIG